Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBanco Santander Regulatory News (BNC)

Share Price Information for Banco Santander (BNC)

Share Price is delayed by 15 minutes
Get Live Data
906.00    10.00 (1.12%)
Bid:
904.00
Ask:
906.00
Spread: 2.00 (0.221%)
Market Cap: £130.35b
BNC Live PriceLast checked at - London Stock Exchange

Intraday Banco Santander Share Chart

New issue: PCCS

18 Apr 2017 07:42

RNS Number : 5546C
Banco Santander S.A.
18 April 2017
 

 

 

 

 

MATERIAL FACT

Banco Santander, S.A. ("Banco Santander" or the "Bank") informs that its Executive Committee has resolved to carry out an issue of contingent perpetual preferred securities convertible into newly issued ordinary shares of the Bank, excluding pre-emptive subscription rights and for a nominal value of up to EUR € 2,000,000,000 (the "Issue"). The Issue will be carried out through an accelerated bookbuilding process and will be targeted only at qualified investors.

Banco Santander will disclose the final terms of the Issue once they have been decided.

 

Boadilla del Monte (Madrid), 18 April 2017

 

 

 

 

 

 

 

IMPORTANT INFORMATION

This material fact does not constitute an offer to sell, or the solicitation of an offer to buy any securities, nor shall there be any sale of such securities in any state of the United States or in another jurisdiction in which such offer, solicitation or sale would not be permitted before registration or qualification under the securities laws of such state or jurisdiction. The securities described above have not been registered under the U.S. Securities Act of 1933, as amended, or any applicable securities laws of any other jurisdiction. Unless so registered, such securities may not be offered or sold in the United States or any other jurisdiction except pursuant to an exemption from the registration requirements of the U.S. Securities Act of 1933, as amended, and any applicable securities laws of such other jurisdiction.

This material fact does not constitute an offer document or an offer of transferable securities to the public in the United Kingdom to which section 85 of the Financial Services and Markets Act 2000 ("FSMA") applies and should not be considered as a recommendation that any person should subscribe for or purchase any of the securities described herein. These securities will not be offered or sold to any person in the United Kingdom except in circumstances which have not resulted and will not result in an offer to the public in the United Kingdom in contravention of section 85(1) of FSMA.

This material fact does not constitute an offer to the public in Italy of financial products, as defined under article 1, paragraph 1, letter (t) of legislative decree no. 58 of 24 February 1998, as amended (the "Financial Services Act"). The preferred securities cannot be offered or sold in the Republic of Italy either on the primary or on the secondary market to any natural persons nor to entities other than qualified investors (investitori qualificati) as defined pursuant to Article 100 of the Financial Services Act and Article 34-ter, paragraph 1, letter b) of Regulation No. 11971 of May 14, 1999, as amended (the "Issuers Regulations") issued by the Commissione Nazionale per le Società e la Borsa, the Italian securities and financial markets regulator ("CONSOB") or unless in circumstances which are exempt from the rules on public offers pursuant to Article 100 of the Financial Services Act and the implementing CONSOB regulations, including the Issuers Regulations. This material fact is for informational purposes only and does not constitute and shall not, in any circumstances, constitute a public offering or an invitation to the public in connection with any offer within the meaning of the Directive 2003/71/EC of the European Parliament and of the Council of 4 November 2003 on the prospectus to be published when securities are offered to the public or admitted to trading.

No action has been made or will be taken that would permit a public offering of any securities described herein in any jurisdiction in which action for that purpose is required. No offers, sales, resales or delivery of any securities described herein or distribution of any offering material relating to any such securities may be made in or from any jurisdiction except in circumstances which will result in compliance with any applicable laws and regulations and which will not impose any obligation on the Company or the Joint Lead Managers or any of their respective affiliates. Additionally, the preferred securities will not be offered, distributed or sold in Spain nor to Spanish residents.

This material fact is an announcement and not a prospectus and investors should not subscribe for or purchase any securities referred herein except on the basis of the information in the offering circular.

Restrictions on Marketing and Sales to Retail Investors

The Preferred Securities are not intended to be sold and should not be sold to retail clients in the European Economic Area, as defined in the rules set out in the Product Intervention (Contingent Convertible Instruments and Mutual Society Shares) Instrument 2015 (as amended or replaced from time to time) (the "PI Rules") other than in circumstances that do not and will not give rise to a contravention of those rules by any person. By making or accepting an offer to purchase any Preferred Securities from the Issuer or the Joint Lead Managers, each prospective investor will be deemed to have represented, warranted, and undertaken to the Issuer and each of the Joint Lead Managers that (i) it is not a retail client; and (ii) it will not take any action which would result in a breach by the Issuer or any other person of the PI Rules (as defined herein). Potential investors should read the whole of the related offering circular, in particular the "Risk Factors" section and the "Restrictions on Marketing and Sales to Retail Investors" section.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCQVLBFDZFZBBB
Date   Source Headline
11th Jun 202611:02 amRNSBuyback programme: transactions 4-10June
10th Jun 20268:35 amRNSResult of Tender Offer
5th Jun 20263:06 pmRNSDirector/PDMR Shareholding
4th Jun 202611:05 amRNSBuyback programme: transactions 28May-3June
1st Jun 20264:47 pmRNSTotal Voting Rights
28th May 20267:00 amRNSAT1s Contingent Convertible securities
27th May 20268:26 amRNSOffer to purchase outstanding instruments
27th May 20268:21 amRNSResumption of the share buyback programme
13th May 20263:03 pmRNSRating granted by Fitch Ratings
6th May 20263:08 pmRNSDirector/PDMR Shareholding
1st May 20267:08 amRNSFurther re: Santander to acquire TSB
30th Apr 20264:59 pmRNSTotal Voting Rights
29th Apr 20267:00 amRNS1Q2026 Financial report & Earnings presentation
29th Apr 20267:00 amRNSFirst Quarter 2026 Results - Press release
24th Apr 202611:14 amRNSBuyback programme: transactions 16-23Apr
23rd Apr 20267:40 amRNSProspectus Exemption
23rd Apr 20267:25 amRNSTemporary suspension of the share buyback program
22nd Apr 202611:09 amRNS1st Quarter 2026 Results Notice
16th Apr 202611:04 amRNSBuyback programme: transactions 8-15Apr
14th Apr 20264:58 pmRNSSantander informs of the MREL determined by SRB
8th Apr 202611:07 amRNSBuyback programme: transactions 26Mar-7Apr
31st Mar 20264:44 pmRNSTotal Voting Rights
27th Mar 20262:26 pmRNS2026 AGM - Resolutions
27th Mar 20267:06 amRNSSantander expects higher profit&reaffirms targets
26th Mar 202610:12 amRNSBuyback programme: transactions 19-25Mar
19th Mar 20265:01 pmRNSDirector/PDMR Shareholding
19th Mar 202611:17 amRNSBuyback programme: transactions 12-18Mar
13th Mar 20264:37 pmRNSDirector/PDMR Shareholding
12th Mar 202611:10 amRNSBuyback programme: transactions 5-11Mar
9th Mar 202611:17 amRNSDirector/PDMR Shareholding
9th Mar 202611:14 amRNSDirector/PDMR Shareholding
6th Mar 20264:18 pmRNSDirector/PDMR Shareholding
5th Mar 202611:16 amRNSBuyback programme: transactions 27Feb-4Mar
4th Mar 20265:58 pmRNSDirector/PDMR Shareholding
2nd Mar 20265:57 pmRNSTotal Voting Rights
27th Feb 202611:18 amRNSBuyback programme: transactions 19-26Feb
25th Feb 20266:01 pmRNSNotice of AGM
25th Feb 20265:20 pmRNS2025 UK Annual Report
25th Feb 20262:19 pmRNSInvestor Day: Group CFO presentation
25th Feb 202612:42 pmRNSInvestor Day: Group CEO presentation
25th Feb 202612:37 pmRNSInvestor Day: Executive chair presentation
25th Feb 20267:03 amRNSStrategic plans, profit forecasts & payout policy
25th Feb 20267:00 amRNSDividend declaration & agreement to call 2026 AGM
24th Feb 20263:05 pmRNSDirector/PDMR Shareholding
23rd Feb 20264:54 pmRNSDirector/PDMR Shareholding
19th Feb 202611:29 amRNSBuyback programme: transactions 12-18Feb
18th Feb 20264:48 pmRNSDirector/PDMR Shareholding
18th Feb 202611:07 amRNSInvestor Day meeting announcement
12th Feb 20263:02 pmRNSBuyback programme: transactions 4-11Feb
10th Feb 20265:09 pmRNSChanges to the presentation of Group’s information

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.